



## Emerging Issue of Inflammatory Bowel Diseases

Guest Editor:

### Dr. Agata Michalak

Department of Gastroenterology  
with Endoscopy Unit, Medical  
University of Lublin, 20-954  
Lublin, Poland

Deadline for manuscript  
submissions:

**closed (31 July 2025)**

### Message from the Guest Editor

Dear Colleagues, Inflammatory bowel diseases (IBDs) are currently crucial pathologies. We still do not know their exact origin, and despite the ongoing era of biologics in their treatment, Crohn's disease and ulcerative colitis tend to be somehow unpredictable in their course. We gather continuously more information related to IBDs. To emphasize the current role of IBDs and to explore molecular pathways involved in their development, we highly encourage you to publish in the Special Issue of Biomedicines titled Emerging Issue of Inflammatory Bowel Diseases. The scope of the manuscripts should be related to the following topics: Original data on novel markers in the diagnosis IBDs and in the prediction of their flare up; Possible new indicators of the positive treatment response; New approaches in the management of IBDs, including combinations of biologics; Markers predicting the natural history of IBDs; Comorbidities observed in patients with IBDs and the general outcome in this population; The context of colorectal cancer in patients with IBDs; Future perspectives for IBDs, including medical and social aspects.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)